dm+d

Unassigned

New Medicines

Fabry's disease in adults and children - second-line

Information

New molecular entity
Chiesi
Protalix

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Pre-registration (Filed)
Yes

Category

Alpha-galactosidase replacement
Fabry disease affects approximately 5,000 to 10,000 people worldwide, but may be under diagnosed
Fabry's disease in adults and children - second-line
Intravenous infusion

Further information

Yes
To be confirmed

Evidence based evaluations